Categorical meta-analysis of osteopontin as a clinical cancer marker

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 433-441

  Weber, Georg F ^a,b   Lett, G Scott ^c   Haubein, Ned C ^c  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b MetaMol Theranostics   (United States)

^c BioAnalytics Group   (United States)

Author keywords

Biomarker; Cancer risk; Etiology; Metastasis

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; META ANALYSIS; METASTASIS; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; UTERINE CERVIX CANCER;

BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; MODELS, THEORETICAL; NEOPLASMS; OSTEOPONTIN; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78651376714     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1106     Document Type: Article

References (32)

1. Senger DR, Wirth DF and Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16: 885-893, 1979.
2. Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869, 2010.
3. Thalheimer W and Cook S: How to calculate effect sizes from published research articles: a simplified methodology. http://www.work-learning.com/ effect-sizes.htm.
4. Cohen J: A power primer. Psychol Bull 112: 155-159, 1992.
5. Hong F, Breitling R, McEntee CW, et al: RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827, 2006. (Pubitemid 44742407)
6. Hong F and Breitling R: A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 24: 374-382, 2008. (Pubitemid 351189013)
7. Agresti A: Categorical Data Analysis. Wiley, New York, 1990.
8. Agresti A: An Introduction to Categorical Data Analysis. 2nd edition. John Wiley and Sons, Inc., Hoboken, NJ, 2007.
9. Rice ME and Harris GT: Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r. Law Hum Behav 29: 615-620, 2005.
10. Moher D, Liberati A, Tetzlaff J and Altman DG; The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535, 2009.
11. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated datamining platform. Neoplasia 6: 1-6, 2004. (Pubitemid 38391943)
12. Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997. (Pubitemid 27387172)
13. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B and Weber GF: Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122: 889-897, 2008.
14. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573, 2005. (Pubitemid 41434635)
15. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH and Lin JT: Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56: 782-789, 2007.
16. Ogbureke KU, Nikitakis NG, Warburton G, Ord RA, Sauk JJ, Waller JL and Fisher LW: Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol 43: 920-932, 2007. (Pubitemid 47376828)
17. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK and Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57: 373-380, 2007. (Pubitemid 47285428)
18. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH and Danenberg PV: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10: 1588-1596, 2004. (Pubitemid 38435547)
19. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V and Li G: Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052, 2005. (Pubitemid 40629107)
20. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL and Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
21. Yang GH, Fan J, Xu Y, Qiu SJ, Yang XR, Shi GM, Wu B, Dai Z, Liu YK, Tang ZY and Zhou J: Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 13: 1155-1165, 2008.
22. Iso Y, Sawada T, Okada T and Kubota K: Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol 92: 304-311, 2005. (Pubitemid 41779288)
23. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH and Jeong SH: Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 101: 2051-2059, 2006. (Pubitemid 44337631)
24. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ and Cerutti JM: Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 14: 4735-4742, 2008.
25. Robbiani DF, Colon K, Ely S, Ely S, Chesi M and Bergsagel PL: Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematol Oncol 25: 16-20, 2007. (Pubitemid 46474310)
26. Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA and Mazzarino MC: Elevated serum levels of Osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biol Ther 4: 1192-1194, 2005.
27. Shin HD, Park BL, Cheong HS, Yoon JH, Kim YJ and Lee HS: SPP1 polymorphisms associated with HBV clearance and HCC occurrence. Int J Epidemiol 36: 1001-1008, 2007.
28. Huang J, Sheng HH, Shen T, Hu YJ, Xiao HS, Zhang Q, Zhang QH and Han ZG: Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett 580: 3571-3581, 2006. (Pubitemid 43902791)
29. Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, Berkowitz RS and Mok SC: Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol 23: 205-212, 2006. (Pubitemid 43780303)
30. Patani N, Jiang W and Mokbel K: Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int J Cancer 122: 2646, 2008. (Pubitemid 351590504)
31. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS and Cramer DW: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12: 432-441, 2006. (Pubitemid 43166132)
32. Bautista DS, Denstedt J, Chambers AF and Harris JF: Low-molecular- weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem 61: 402-409, 1996.